心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Cell Reports：LDL-C为癌转移重要因素

2014-05-15 高晓方 译 医学论坛网

LDL-C癌细胞转移
关注

澳大利亚一项研究表明，低密度脂蛋白胆固醇(LDL-C)为癌细胞转移的重要因素，胆固醇水平调节有望成为预防癌症转移的方法。论文发表于《细胞报告》(Cell Reports)。【原文下载】 远处转移为癌症的主要死因之一，深入了解癌症转移机制可显著改善癌症治疗。细胞表面粘附分子整合素有助于癌细胞脱离肿瘤并在其他部位定植，因此阻断整合素可防止癌细胞迁移和扩散，但目前研发的整合素抑制剂并不适用于临床。

澳大利亚一项研究表明，低密度脂蛋白胆固醇(LDL-C)为癌细胞转移的重要因素，胆固醇水平调节有望成为预防癌症转移的方法。论文发表于《细胞报告》(Cell Reports)。【原文下载】



远处转移为癌症的主要死因之一，深入了解癌症转移机制可显著改善癌症治疗。细胞表面粘附分子整合素有助于癌细胞脱离肿瘤并在其他部位定植，因此阻断整合素可防止癌细胞迁移和扩散，但目前研发的整合素抑制剂并不适用于临床。




既往研究发现，整合素可由细胞表面迁移至细胞内，胆固醇则是将整合素保持在细胞表面的必需因素。此项研究表明，LDL-C可控制包括整合素在内物质运输，并且其对癌症细胞迁移和扩散能力具有显著影响。高水平LDL-C有助于癌细胞整合素移位至细胞表面，高水平HDL-C则可将整合素保持在细胞内。调节胆固醇水平有望成为影响癌细胞迁移和浸润的方法。

原始出处：

Cancer spreads with help from 'bad' cholesterol.MNT May 9 2014 

Reverter M1, Rentero C1, Garcia-Melero A1, Hoque M2, Vilà de Muga S1, Alvarez-Guaita A1, Conway JR3, Wood P2, Cairns R2, Lykopoulou L4, Grinberg D5, Vilageliu L5, Bosch M6, Heeren J7, Blasi J8, Timpson P3, Pol A9, Tebar F10, Murray RZ11, Grewal T12, Enrich C13.Cholesterol Regulates Syntaxin 6 Trafficking at trans-Golgi Network Endosomal Boundaries.Cell Rep. 2014 May 8;7(3):883-97. doi: 10.1016/j.celrep.2014.03.043. Epub 2014 Apr 17.【原文下载】

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959064, encodeId=220a195906405, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu May 29 04:06:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868821, encodeId=2707186882104, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Apr 24 08:06:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422516, encodeId=d9bf1422516f1, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Sat May 17 05:06:00 CST 2014, time=2014-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590251, encodeId=8f151590251a4, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 17 05:06:00 CST 2014, time=2014-05-17, status=1, ipAttribution=)]
    2014-05-29 维他命

    #CEL#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1959064, encodeId=220a195906405, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu May 29 04:06:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868821, encodeId=2707186882104, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Apr 24 08:06:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422516, encodeId=d9bf1422516f1, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Sat May 17 05:06:00 CST 2014, time=2014-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590251, encodeId=8f151590251a4, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 17 05:06:00 CST 2014, time=2014-05-17, status=1, ipAttribution=)]
    2015-04-24 zhaozhouchifen

    #Cell#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1959064, encodeId=220a195906405, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu May 29 04:06:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868821, encodeId=2707186882104, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Apr 24 08:06:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422516, encodeId=d9bf1422516f1, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Sat May 17 05:06:00 CST 2014, time=2014-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590251, encodeId=8f151590251a4, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 17 05:06:00 CST 2014, time=2014-05-17, status=1, ipAttribution=)]
    2014-05-17 zhwj

    #LDL#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1959064, encodeId=220a195906405, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu May 29 04:06:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868821, encodeId=2707186882104, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Apr 24 08:06:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422516, encodeId=d9bf1422516f1, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Sat May 17 05:06:00 CST 2014, time=2014-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590251, encodeId=8f151590251a4, content=<a href='/topic/show?id=2c17e154824' target=_blank style='color:#2F92EE;'>#癌转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71548, encryptionId=2c17e154824, topicName=癌转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc017794099, createdName=linagood, createdTime=Sat May 17 05:06:00 CST 2014, time=2014-05-17, status=1, ipAttribution=)]
    2014-05-17 linagood

    #癌转移#

    0

相关资讯

Nat Rev Cardiol：2013血脂防治进展：新他汀指南和潜在新的治疗方法

　　ACC/AHA新版胆固醇治疗指南（以下简称：新指南）调强了他汀类药物的强化治疗。早期研究表明PCSK9抑制剂能显著降低低密度脂蛋白（LDL-C）水平。同时，MicroRNA沉默和基因修复技术有望成为治疗血脂紊乱新策略。本文主要讨论2013年血脂紊乱预防和治疗进展。 　　新指南并未设定LDL-C和非HDL-C目标值，而是强调他汀类药物的强化治疗和生活方式的改善 　　

Clin Cardiol：Evolucumab降低LDL-C（LAPLACE-2和RUTHERFORD-2试验）

分别于1月28日和30日公布的LAPLACE-2和RUTHERFORD-2两项研究显示，Evolucumab可显著降低LDL-C水平。1. LAPLACE-2研究根据1月28日公布的LAPLACE-2研究结果，Evolucumab+他汀较单用他汀显著降低原发性高胆固醇血症和混合型血脂异常患者的LDL-C水平。Jennifer Robinson博士（爱荷华大学）将于2014年3月30日召开的美国

ACC 2014：多研究证明Evolocumab降脂的有效性

2014年美国心脏病学会年会（ACC2014）公布的三项临床试验表明，PCSK9单克隆抗体Evolocumab可有效降低高脂血症患者的低密度脂蛋白胆固醇（LDL-C），并且具有较好的安全性。 DESCARTES试验共纳入901例经降脂治疗后LDL-C ≥ 75 mg/dL的受试者，并按照2:1比率随机分入evolocumab（420 mg 皮下注射 1次/月）或安慰剂组。结果显示，evolocu

李建军：LDL-C靶目标探索之我见

降低胆固醇在心血管疾病防治中发挥着极为重要的作用，血脂异常的首要干预目标是降低低密度脂蛋白胆固醇（LDL-C）。他汀20余年的发展和大量的循证医学证据奠定了其成为调脂治疗的基石和降LDL-C的首选药物。他汀类药物的系列研究显示，LDL-C在一定范围内“低一点更好”。但人类至今尚未找到LDL-C安全而有效的确切靶目标，是否存在类似血压和血糖的“J”型曲线尚待阐明。因而学术

Diabetes Care：LDL-C和HbA1c同时达标可带来多重获益

近期一项研究表明，同时实现LDL-C和HbA1c达标可为2型糖尿病患者带来明显的临床和经济获益。研究结果发表于10月刊《糖尿病护理》杂志。 研究简介 本项回顾性队列分析评估了2004年至2010年间测定低密度脂蛋白胆固醇（LDL-C）和糖化血红蛋白（HbA1c）2次或以上的成年2型糖尿病患者的电子病历（退伍军人综合服务网络16） .主要目的是评估与HbA1c和L

胡大一：我国当前血脂异常治疗的15条建议

血脂异常的治疗成为2013年下半年心血管医学界最引入关注的热门话题。继先前发布的欧洲心脏病学学会和欧洲动脉粥样硬化学会指南之后，2013年7月和12月分别公布了国际动脉粥样硬化学会(IAS)的建议和美国心脏协会(AHA)/美国心脏病学学会(ACC)的指南。这3个学术影响较大的指南类文件在形式与内涵上出现了巨大差别，引起了国内外学术机构与广大临床医生的关注与质疑。国内已开展了多次讨论，2007年